438 related articles for article (PubMed ID: 12656747)
21. Lymphoid blast crisis during complete cytogenetic remission following interferon-alpha and hydroxyurea therapy.
Bose S; Chowdhry VP; Saxena R; Kucheria K
Acta Haematol; 1997; 98(3):155-9. PubMed ID: 9352747
[TBL] [Abstract][Full Text] [Related]
22. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
Braziel RM; Launder TM; Druker BJ; Olson SB; Magenis RE; Mauro MJ; Sawyers CL; Paquette RL; O'Dwyer ME
Blood; 2002 Jul; 100(2):435-41. PubMed ID: 12091333
[TBL] [Abstract][Full Text] [Related]
23. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
[TBL] [Abstract][Full Text] [Related]
24. Resistance in the land of molecular cancer therapeutics.
Shannon KM
Cancer Cell; 2002 Aug; 2(2):99-102. PubMed ID: 12204529
[TBL] [Abstract][Full Text] [Related]
25. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
26. Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes.
Jiang G; Yang F; Li M; Weissbecker K; Price S; Kim KC; La Russa VF; Safah H; Ehrlich M
Cancer Biol Ther; 2003; 2(1):103-8. PubMed ID: 12673129
[TBL] [Abstract][Full Text] [Related]
27. Cytogenetic and molecular mechanisms of resistance to imatinib.
Hochhaus A
Semin Hematol; 2003 Apr; 40(2 Suppl 2):69-79. PubMed ID: 12783379
[TBL] [Abstract][Full Text] [Related]
28. Integration of amplified BCR/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia.
Metzke-Heidemann S; Harder L; Gesk S; Schoch R; Jenisch S; Grote W; Siebert R; Schlegelberger B
Genes Chromosomes Cancer; 2001 May; 31(1):10-4. PubMed ID: 11284030
[TBL] [Abstract][Full Text] [Related]
29. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
von Bubnoff N; Peschel C; Duyster J
Leukemia; 2003 May; 17(5):829-38. PubMed ID: 12750693
[TBL] [Abstract][Full Text] [Related]
30. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations.
Mohamed AN; Pemberton P; Zonder J; Schiffer CA
Clin Cancer Res; 2003 Apr; 9(4):1333-7. PubMed ID: 12684401
[TBL] [Abstract][Full Text] [Related]
31. Salvage chemotherapy with donor lymphocyte infusion and STI 571 in a patient relapsing with B-lymphoblastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation.
Gopcsa L; Barta A; Bányai A; Dolgos J; Halm G; Pálóczi K
Pathol Oncol Res; 2003; 9(2):131-3. PubMed ID: 12858220
[TBL] [Abstract][Full Text] [Related]
32. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Shah NP; Nicoll JM; Nagar B; Gorre ME; Paquette RL; Kuriyan J; Sawyers CL
Cancer Cell; 2002 Aug; 2(2):117-25. PubMed ID: 12204532
[TBL] [Abstract][Full Text] [Related]
33. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction.
Stentoft J; Pallisgaard N; Kjeldsen E; Holm MS; Nielsen JL; Hokland P
Eur J Haematol; 2001; 67(5-6):302-8. PubMed ID: 11872078
[TBL] [Abstract][Full Text] [Related]
34. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Sawyers CL
Semin Hematol; 2001 Jul; 38(3 Suppl 8):15-21. PubMed ID: 11526597
[TBL] [Abstract][Full Text] [Related]
35. STI571: a gene product-targeted therapy for leukemia.
Mauro MJ; Druker BJ
Curr Oncol Rep; 2001 May; 3(3):223-7. PubMed ID: 11296132
[TBL] [Abstract][Full Text] [Related]
36. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
Hofmann WK; Komor M; Wassmann B; Jones LC; Gschaidmeier H; Hoelzer D; Koeffler HP; Ottmann OG
Blood; 2003 Jul; 102(2):659-61. PubMed ID: 12663457
[TBL] [Abstract][Full Text] [Related]
37. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.
Gambacorti-Passerini CB; Gunby RH; Piazza R; Galietta A; Rostagno R; Scapozza L
Lancet Oncol; 2003 Feb; 4(2):75-85. PubMed ID: 12573349
[TBL] [Abstract][Full Text] [Related]
38. Chronic myelogenous leukemia.
Mauro MJ; Druker BJ
Curr Opin Oncol; 2001 Jan; 13(1):3-7. PubMed ID: 11148678
[TBL] [Abstract][Full Text] [Related]
39. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.
Olavarria E; Craddock C; Dazzi F; Marin D; Marktel S; Apperley JF; Goldman JM
Blood; 2002 May; 99(10):3861-2. PubMed ID: 11986250
[TBL] [Abstract][Full Text] [Related]
40. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.
Gorre ME; Ellwood-Yen K; Chiosis G; Rosen N; Sawyers CL
Blood; 2002 Oct; 100(8):3041-4. PubMed ID: 12351420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
